deltatrials
Completed PHASE2 INTERVENTIONAL 3-arm NCT01190787

Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone

A Multicenter Phase II Study of Subcutaneous Velcade Plus Oral Melphalan and Prdnisone or Plus Cycloposphamide and Prednisone or Plus Prednisone in Newly Diagnosed Elderly Multiple Myeloma Patients

Sponsor: European Myeloma Network B.V.

Conditions Multiple Myeloma
Interventions velcade cyclophosphamide prednisone velcade prednisone velcade subcutaneous melphalan prednisone
Updated 15 times since 2017 Last updated: Jan 19, 2024 Started: Jul 31, 2010 Primary completion: May 31, 2012 Completion: Jan 18, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Multiple Myeloma and is currently completed. European Myeloma Network B.V. leads this study, which shows 15 recorded versions since 2010 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Sep 2020 · 24 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Mar 2022 · 12 months · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~Mar 2023 · 11 months · monthly snapshot~Mar 2023 – ~Feb 2024 · 11 months · monthly snapshot~Feb 2024 – ~Mar 2024 · 29 days · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – present · 22 months · monthly snapshot

Change History

15 versions recorded

  1. Nov 2024 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Nov 2024 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Mar 2024 — Jul 2024 [monthly]

    Completed PHASE2

  5. Feb 2024 — Mar 2024 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 10 earlier versions

  1. Mar 2023 — Feb 2024 [monthly]

    Active Not Recruiting PHASE2

  2. Apr 2022 — Mar 2023 [monthly]

    Active Not Recruiting PHASE2

    Status: Unknown Status → Active Not Recruiting

  3. Mar 2022 — Apr 2022 [monthly]

    Unknown Status PHASE2

    Status: Active Not Recruiting → Unknown Status

  4. Mar 2021 — Mar 2022 [monthly]

    Active Not Recruiting PHASE2

    Status: Unknown Status → Active Not Recruiting

  5. Feb 2021 — Mar 2021 [monthly]

    Unknown Status PHASE2

  6. Jan 2021 — Feb 2021 [monthly]

    Unknown Status PHASE2

  7. Sep 2020 — Jan 2021 [monthly]

    Unknown Status PHASE2

    Status: Active Not Recruiting → Unknown Status

  8. Sep 2018 — Sep 2020 [monthly]

    Active Not Recruiting PHASE2

  9. Jun 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE2

  10. Jan 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Jul 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • European Myeloma Network B.V.
  • Fondazione EMN Italy Onlus
Data source: European Myeloma Network B.V.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations